Chi­na’s rapid ad­vance in biotech will slow as com­pa­nies there be­gin to ex­per­i­ment on the cut­ting edge of R&D, ac­cord­ing to Pfiz­er’s An­drew Baum, who...

Bio­Marin drops rare dis­ease as­set af­ter mixed Phase 3: Bio­Marin de­cid­edto dis­con­tin­ue de­vel­op­ment of BMN401, an en­zyme re­place­ment ther­a­py for ENPP1 de­fi­cien­cy, the biotech...

A can­cer biotech vy­ing for a piece of As­traZeneca's can­cer ter­ri­to­ry and a pain spe­cial­ist chas­ing Ver­tex's land­mark non-opi­oid drug are cap­ping an IPO-heavy week...

→ One of the most in­flu­en­tial phar­ma ex­ecs at John­son & John­son is re­tir­ing. Jen­nifer Taubert, the world­wide chair of John­son & John­son In­no­v­a­tive...